Product
PD-L1 t-haNK cells
1 clinical trial
2 indications
Clinical trial
A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-12-01